A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study

Journal of Thrombosis and Thrombolysis

Volumn 20, Issue 3, 2005, Pages 147-153

  Jang, Ik Kyung ^a   Pettigrew, Veronica ^b   Picard, Michael H ^a   Kowey, Peter R ^c   Demmel, Valentin ^d   Zile, Michael R ^e   Tatsuno, Jun ^f   Wackers, Frans J Th ^g   Hibberd, Mark ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Mitsubishi Pharma America Inc   (United States)

^c Main Line Health Heart Center   (United States)

^d Nabios   (Germany)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^g YALE UNIVERSITY   (United States)

^h CardioCorp   (United States)

Author keywords

Left ventricular function; Percutaneous coronary intervention; Single photon emission computed tomography; ST elevation myocardial infarction

Indexed keywords

5 METHYL 2 (PIPERAZIN 1 YL)BENZENE SULFONIC ACID; CALCIUM CHANNEL BLOCKING AGENT; MCC 135; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BENZENESULFONATES; CALCIUM; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MUSCLE CELLS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NECROSIS; PIPERAZINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT;

EID: 27944443713     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-3267-4     Document Type: Article

References (26)

1. Shihara M, Tsutsui H, Tsuchihashi M, Tada H, Kono S, Takeshita A. for the Japanese Coronary Invention Study (JCIS) Group. In-hospital and one-year outcomes for patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2002;90:932-936. 10.1016/S0002-9149(02)02656-5
2. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945-2951. 11113044
3. Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903. 10.1056/NEJM200106213442503
4. Tcheng JE, Kandzari DE, Grines CL, et al. For the CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003;108:1316-1323. 10.1161/ 01.CIR.0000087601.45803.86
5. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
6. Topol EJ, Mark DB, Lincoff AM, et al. For the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet. 1999;354:2019-2024. 10.1016/ S0140-6736(99)10018-7
7. Castro PF, Larrain G, Baeza R, et al. Effects of glucose-insulin-potassium solution on myocardial salvage and left ventricular function after primary angioplasty. Crit Care Med. 2003;31:2152-2155. 10.1097/01.CCM.0000079604.46997.7B
8. Stone GW, Webb J, Cox DA, et al. For EMERALD Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: A randomized controlled trial. JAMA. 2005;293:1063-1072. 10.1001/jama.293.9.1063
9. Granger CB, Mahaffey KW, Weaver WD, et al. for the COMMA investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-1190. 10.1161/ 01.CIR.0000087447.12918.85
10. Mahaffey KW, Granger CB, Nicolau JC, et al. For the COMPLY Investigators. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176-1183. 10.1161/ 01.CIR.0000087404.53661.F8
11. Mahaffey KW, Puma JA, Barbagelata NA, et al. For the AMISTAD Investigators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711-1720. 10.1016/ S0735-1097(99)00418-0
12. Ross AM, Gibbons R, Kloner RA, et al. Acute myocardial infarction study of adenosine (AMISTAD II). Paper presented at the American College of Cardiology 51st Annual Meeting; March 17-20, 2002; Atlanta, Georgia.
13. Theroux P, Chaitman BR, Danchin N, et al. For the GUARd During Ischemia Against Necrosis (GUARDIAN) Investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: Main results of the GUARDIAN trial. Circulation. 2000;102:3032-3038. 11120691
14. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001;38:1644-1650. 10.1016/ S0735-1097(01)01608-4
15. Dixon SR, Rizik DG, Griffin JJ, et al. For the COOL-MI Investigators. A Prospective, Randomized Trial of Mild Hypothermia During Primary Percutaneous Intervention for Acute Myocardial Infarction (COOL-MI): One-Year Clinical Outcome. Paper presented at the American College of Cardiology 53rd Annual Meeting; March 7-10, 2004; New Orleans, Louisiana.
16. O'Neill WW, Martin JL, Dixon SR, et al. For the AMIHOT Investigators. Acute Myocardial Infarction With Hyperoxemic Therapy (AMIHOT): A Prospective, Randomized, Multicenter Trial. Paper presented at the American College of Cardiology 53rd Annual Meeting; March 7-10, 2004; New Orleans, Louisiana.
17. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332-2336. 10.1161/ 01.CIR.0000016602.96363.36
18. Shigekawa M, Iwamoto T. Cardiac Na(+)-Ca(2+) exchange: Molecular and pharmacological aspects. Circ Res. 2001;88:864-876. 11348995
19. 2+ overload in ischemic/reperfused hearts. Eur J Pharmacol. 2004;499:179-187. 10.1016/j.ejphar.2004.07.095
20. Satoh N, Sato T, Shimada M, Yamada K, Kitada Y. Lusitropic effect of MCC-135 is associated with improvement of sarcoplasmic reticulum function in ventricular muscles of rats with diabetic cardiomyopathy. J Pharmacol Exp Ther. 2001;298:1161-1166. 11504815
21. Kawasumi H, Satoh N, Abe Y, Narimatsu A, Kitada Y. MCC-135, a new agent for the treatment of heart diseases. Japanese J Pharmacol. 1998;76(suppl I):277P.
22. Yarbrough WM, Mukherjee R, Escobar GP, et al. Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg. 2003;76:2054-2061. 10.1016/S0003-4975(03)01059-2
23. Tzivoni D, Baer F, Ortiz AF, et al. Reduction of Infarct Size and Improved Left Ventricular Function With Intravenous Caldaret (MCC-135) and Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction. Paper presented at the American College of Cardiology 53rd Annual Meeting; March 7-10, 2004; New Orleans, Louisiana.
24. Boersma H, Maas ACP, Grijseels EWM, Deckers JW, Hartman JAM, Simoons ML. Benefits and risks of possible prehospital thrombolysis strategies-the role of the electrocardiogram. Cardiologie. 1998;5:562-568.
25. Grijseels EW, Bouten MJ, Lenderink T, et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase: Practical applications, complications and long-term results in 529 patients. Eur Heart J. 1995;16:1833-1838. 8682015
26. nQuery Advisor® 4.0, Statistical Solutions Ltd., Saugus, MA.